today. Lisa, and us very you joining you, Thank for good morning, thank everyone, much and
COVID-XX made onset chronic decision the hepatitis founded of the be in innovative candidates was preclinical development and compounds is to pipeline, expertise expanded with market well portfolio Arbutus a to could core of our of treatment patients and virologists a as focus our actively goal by strategic advancing we in B that our expand for pandemic COVID-XX on as virus clinical include regimen. combined leverage developing developing discovering, cure advancing team large with that Arbutus XXXX, assets Now clinical our functional their treatment the coronavirus and the opportunities. With future commercializing broad options antiviral of a for outbreaks. At developing focus to create the our to address of today
RNAi We need, HBV. suited believe advanced AB-XXX, are we patients address HBV, RNAi the is a reducing to both over surface response. generated to DNA, chronic XXX coronavirus chronic for and need And with effective of therapeutic there our in are in less treatment franchises. are current the a resulting shown believe require encouraged suppressing in date, and worldwide large antigen for needed advances We of HBV to data only a compounds HBV unmet HBV made AB-XXX cure we've There Based cure this people by million to with we most medical and X% who impact chronically X is components for a HBV. for which the infected and both options with well functional remains development. that combination functional all cure than one therapeutics reawakening success, are namely on lifelong beginning coronavirus immune the with rate, HBV-specific achieve a chronic
its Given HBV. chronic a patients potential AB-XXX believe far, therapy compelling cornerstone the that provide for with functional thus we has data cure a to to be
we our Both data expect preliminary one with X exploring of and evaluate HPV products interferon expected combination strategy trials, have investigational that to stage in trials. this later approved Xa potentially year help that immunotherapeutic. inform are We're other the trials XXX these and to in combination with combination with through clinical Phase combination one Vaccitech's will ongoing antigen-specific
moment clinical provide our to Before ongoing to I discuss first I'd X from these Phase though, like trials a trial. combination data take
least levels of X.X or Phase produces interval recently reported at our declines showed treatment and from data for that years in X same treated week, comparable and show with trial antigen DNA X Furthermore, baseline after characteristics. last dose Summit of XXX Now X dosing XXX. HBV XXX of patients robust low surface from examined the as dose, that we at of surface Hepatitis last clinical their persisting Global antigen, trial regardless
Now trials. in interferon plan are look for last to courses additional year, either include We of of data evaluating NUC receive clinical this from XXX data of in therapy The first trial to our with randomized we back the and or report trial short additional preliminary new this combination of is shared which weeks. first now have AB-XXX-XXX. combination to that preliminary forward plus going further validated XXX's to received reduce or XX reporting the Patients will the in data XX patients Phase some XXXX lead-in surface combination these ongoing being Xa ongoing the interferon. half antigen. from minus doses plus capacity of to The half therapy ongoing trial We late phase interferon. year XXX XXX who
we Vaccitech's half second Xa the AB-XXX-XXX, immune a surface NUC preliminary data or XXXX, VTP-XXX in combination Phase trial host Xb/Xa of our reported can Phase suppress for of to therapy the HBV that In VTP-XXX trial, immunotherapeutic VTP-XXX Vaccitech fully from XXX antigen combination data to placebo. virus. and of expect sustained evaluating system the antigen showing enough HBV-specific and recently are lower we from clinical is the chronic reductions testing induced whether which patients. meaningful report has Through XXX some surface trial, this the
a cancers trial to we're name arm Opdivo. reminder, brand number latter to inhibitor to PD-X additional the which the a low-dose include As with an nivolumab expand under approved a antibody of is preparing treat monoclonal
the trial. the determine first adding reduction And known more an mediated update begin to combination we of will dose enrollment stimulate the further after arm the commonly we'll XXX VTP-XXX. immune treatment when addition to this if VTP-XXX as provide surface of are nivo, of of antigen nivolumab, in of nivo and We initial new the
healthy developing Phase being of our trial combination developed treatment as our is X RNA HBV-specific a AB-XXX HBV. proprietary to dosed HBV, of potential for strategy subject the the in chronic our clinical in of functionally with March. part with destabilizer, regimen consistent is oral addition, oral which cure treatment In first a next-generation AB-XXX we
vitro chronic action of We in functional a at suggest expect combination HBV surface year. component XXX of anti-HBV that important of The the RNA differentiated to this mode XXX data classes and to Global provide second anti-HBV showing in HBV of portion in and be robust Hepatitis Summit preclinical to of the the compared other that Notably, single an ascending may antigen half vivo. past dose suppression we of trial this from HBV. cure for data inhibitors XXX initial have provides presented in activity, including this April,
for disappointing Now received our week, placed last the clinical oral we that PD-LX on the AB-XXX, inhibitor, IND the application hold. FDA news
not Just AB-XXX. be Phase any do Therefore, we X this we initial the had the XXXX. dosed clinical half clear, have to will clinical second half not trial in Phase of and the we patients this not data first to trial XXX and X trial with year, the initiate not had been expect of in initiated, with from
continue combination HBV. authorities will be in forward with however, it we therapy to important our regulatory AB-XXX will, an component to believe move to We work designed as cure
coronavirus antiviral momentum our developing COVID-XX our to small continue and talented to future is build on outbreaks. treat identifying that team with molecules focused significant on Now also new we and
and to are across address highly develop not active replication the against critical are ritonavir that We've essential oral main SARS-CoV-X are known enzymes boosting. selected the conserved lead all These antiviral urgent advancing nspXX coronavirus recently inhibitor strategy the enzymes and for the cycle, as and identify need require We compounds our protease, viral and for AB-XXX circulating variants life to target are nspX therapies potent actively that also X Mpro our polymerase. known Mpro for as compound SARS-CoV-X both coronaviruses. oral do and viral
we and and shared SARS-CoV-X is showing antiviral preclinical resistance inhibitor, in prestigious supporting in of from AB-XXX, against and potent currently favorable X activity its data a vitro treatment. ICAR profile pan-coronavirus impressive, the profile at favorable oral studies, Preclinical activity, congresses, Mpro AB-XXX we're variants, of several PK Recently, our IND-enabling IRV, ritonavir-free of development details namely and of and differentiated initiate Phase to regimen therapy an development. trial the will treatment nspXX optimal both second products just X studies such year. inhibitor and one be plan coronavirus believe from of an half this the inhibitor in Mpro We in is consist piece our a strategy. will a other IS clinical AB-XXX that
our in the these that So into which of X to end, the this half goal more be nspXX throughout progress year. second to programs on sharing we studies an We'll as and then nominate we year. can inhibitor, updates IND-enabling is take identify
the call brief over financial a to turn Dave now Hastings I'll for update.
